Health

Eli Lilly's Weight Loss Drug Cuts Diabetes Risk by 94% in Long-Term Trial

Aug 20, 2024 1 min read

Jump to Summary

Eli Lilly's weight loss drug, tirzepatide, has shown promising results in reducing the risk of developing type 2 diabetes by 94% in obese or overweight adults with pre-diabetes. This data comes from a three-year follow-up of the late-stage trial known as SURMOUNT-1. The study, which included over 1,000 participants, also indicated significant sustained weight loss. Adults on the highest weekly dose of the drug experienced an average weight reduction of 22.9% over 176 weeks, compared to a 2.1% decrease for those on a placebo.

The findings suggest that tirzepatide, marketed as Zepbound for weight loss, could potentially delay the progression to diabetes in high-risk individuals. Eli Lilly plans to submit these results to a peer-reviewed journal and present them at an upcoming medical conference in November. The safety profile of tirzepatide remained consistent with previous studies, according to Jeff Emmick, Lilly's senior VP of product development. The company is also exploring the extension of its obesity drugs to treat related conditions such as sleep apnea and heart disease.

#finance #markets #nutrition #business #lifestyle #fitness

Summary

Other news in health

China to Permit Foreign-Owned Hospitals in Major Urban Centers

China has announced that it will fully open its manufacturing sector to foreign investments and allow more room for foreign capital in its health sector starting from November 1. The National Development and Reform Commission (NDRC) will remove the last remaining limits on overseas investments in the manufacturing sector and

Couche-Tard Renews Bid for Seven & i After $38.5 Billion Rejection

Alimentation Couche-Tard is making a renewed effort to acquire Seven & i Holdings, the Japanese operator of 7-Eleven, after its initial $38.5 billion offer was rejected. The Canadian convenience retailer plans to write to Seven & i in the coming days to reiterate its interest and may even take

New vaccine emerges for a little-known deadly virus affecting over-75s

The NHS has launched its first-ever RSV vaccination campaign aimed at protecting vulnerable groups from the respiratory syncytial virus, which can cause severe breathing difficulties in young children and older adults. The campaign focuses on adults aged 75 to 79 and pregnant women, who can pass on RSV antibodies to

YouTuber Nikocado Avocado Stuns Fans With 113kg Weight Loss in 7 Months

Nicholas Perry, known as Nikocado Avocado, has returned to YouTube after a seven-month hiatus, revealing a significant weight loss of 250 pounds. The transformation has sparked widespread discussion on social media platforms like X (formerly Twitter) and Reddit. While many fans expressed admiration, others speculated that his rapid weight loss